Protagonist Therapeutics, Inc Defined Contribution Plan, Cost
Protagonist Therapeutics, Inc (PTGX) reported Defined Contribution Plan, Cost of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-25
- Protagonist Therapeutics, Inc defined contribution plan, cost for the quarter ending 2021-12-31 was $0.00.
- Protagonist Therapeutics, Inc defined contribution plan, cost for the quarter ending 2021-09-30 was $100.00K.
- Protagonist Therapeutics, Inc defined contribution plan, cost for the quarter ending 2021-06-30 was $0.00.
- Protagonist Therapeutics, Inc defined contribution plan, cost for the quarter ending 2020-03-31 was $0.00.
- Protagonist Therapeutics, Inc defined contribution plan, cost for fiscal 2025 was $500.00K, a 25.00% increase from fiscal 2024.
- Protagonist Therapeutics, Inc defined contribution plan, cost for fiscal 2024 was $400.00K, a 0.00% change from fiscal 2023.
- Protagonist Therapeutics, Inc defined contribution plan, cost for fiscal 2023 was $400.00K, a 33.33% increase from fiscal 2022.
- Protagonist Therapeutics, Inc defined contribution plan, cost for fiscal 2022 was $300.00K, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $400.00K 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $400.00K 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $300.00K 10-K · filed 2025-02-21 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $100.00K derived: sum of 2 quarters · filed 2024-02-27 | $100.00K derived: sum of 3 quarters · filed 2024-02-27 | $300.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-03 | $100.00K derived: sum of 2 quarters · filed 2021-11-03 | $300.00K 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-04 | $200.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |